Clinical Trial

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-10-26; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT06104592
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Kite, A Gilead Company
Conditions Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Enrollment 27 participants
Start Date 2023-11-08
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-31